Sunitinib, a receptor tyrosine kinase inhibitor, and chemotherapeutic agent is used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) is a hybrid of isatin and pyrrole pharmacophores. The gene discussed is NTRK1; the disease is renal cell carcinoma.